Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 2/2015

01-04-2015 | Review Article

Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer

Authors: Hirotaka Iwase, Yutaka Yamamoto

Published in: International Journal of Clinical Oncology | Issue 2/2015

Login to get access

Abstract

Sequential use of endocrine agents is common in estrogen receptor (ER)-positive metastatic breast cancer (MBC). In premenopausal women with MBC, tamoxifen and/or a luteinizing hormone-releasing hormone (LH-RH) agonist are options for endocrine treatment. Meta-analysis showed that the combination of the two agents is superior to either monotherapy. Under ovarian ablation or function-suppression, an agent used to treat postmenopausal women, such as the aromatase inhibitor (AI), fulvestrant, becomes possible as a subsequent therapy. In postmenopausal women, endocrine treatment options are widely available and an optimal sequence has not yet to be determined. Options for first-line therapy of metastatic disease include an AI for women who have received adjuvant tamoxifen, or tamoxifen for patients who have received adjuvant AI. In addition, data suggest that fulvestrant is a promising therapeutic option that has proven efficacy in the treatment of postmenopausal women with MBC. Other agents that may be used in the sequence include a steroidal AI or a progestin. Furthermore, estrogen additive therapy by with diethylstilbestrol or ethinylestradiol has recently been revived and showed a high response rate as a salvage endocrine therapy, although its mechanism of action is still unclear. Thus, sequential use of endocrine therapies, especially the use of a subsequent therapy with a different mechanism of action to the prior therapy, has a beneficial effect in maintaining a good quality of life and extending survival for MBC with hormone responsiveness.
Literature
1.
Iwase H, Kurebayashi J, Tsuda H et al (2010) Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. (Translated from Eng). Breast Cancer 17(2):118–124 (in Eng)CrossRefPubMed
2.
Crump M, Sawka CA, DeBoer G et al (1997) An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. (Translated from Eng). Breast Cancer Res Treat 44(3):201–210 (in Eng)CrossRefPubMed
3.
Klijn JG, Blamey RW, Boccardo F et al (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. (Translated from Eng). J Clin Oncol 19(2):343–353 (in Eng)PubMed
4.
Klijn JG, Beex LV, Mauriac L et al (2000) Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. (Translated from Eng). J Natl Cancer Inst 92(11):903–911 (in Eng)CrossRefPubMed
5.
Boccardo F, Rubagotti A, Perrotta A et al (1994) Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. (Translated from Eng). Ann Oncol 5(4):337–342 (in Eng)PubMed
6.
Taylor CW, Green S, Dalton WS et al (1998) Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. (Translated from Eng). J Clin Oncol 16(3):994–999 (in Eng)PubMed
7.
Forward DP, Cheung KL, Jackson L et al (2004) Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. (Translated from Eng). Br J Cancer 90(3):590–594 (in Eng)CrossRefPubMedCentralPubMed
8.
Carlson RW, Theriault R, Schurman CM et al (2010) Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. (Translated from Eng). J Clin Oncol 28(25):3917–3921 (in Eng)CrossRefPubMed
9.
Nishimura R, Anan K, Yamamoto Y et al (2013) Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial. (Translated from Eng). Oncol Rep 29(5):1707–1713 (in Eng)PubMedCentralPubMed
10.
Bartsch R, Bago-Horvath Z, Berghoff A et al (2012) Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. (Translated from Eng). Eur J Cancer 48(13):1932–1938 (in Eng)CrossRefPubMed
11.
Willemse PH, van der Ploeg E, Sleijfer DT et al (1990) A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. (Translated from Eng). Eur J Cancer 26(3):337–343 (in Eng)CrossRefPubMed
12.
Nabholtz JM, Buzdar A, Pollak M et al (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. (Translated from Eng). J Clin Oncol 18(22):3758–3767 (in Eng)PubMed
13.
Bonneterre J, Thurlimann B, Robertson JF et al (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. (Translated from Eng). J Clin Oncol 18(22):3748–3757 (in Eng)PubMed
14.
Bonneterre J, Buzdar A, Nabholtz JM et al (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. (Translated from Eng). Cancer 92(9):2247–2258 (in Eng)CrossRefPubMed
15.
Mouridsen H, Gershanovich M, Sun Y et al (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. (Translated from Eng). J Clin Oncol 21(11):2101–2109 (in Eng)CrossRefPubMed
16.
Paridaens RJ, Dirix LY, Beex LV et al (2008) Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. (Translated from Eng). J Clin Oncol 26(30):4883–4890 (in Eng)CrossRefPubMedCentralPubMed
17.
Mauri D, Pavlidis N, Polyzos NP et al (2006) Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. (Translated from Eng). J Natl Cancer Inst 98(18):1285–1291 (in Eng)CrossRefPubMed
18.
Howell A, Robertson JF, Abram P et al (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. (Translated from Eng). J Clin Oncol 22(9):1605–1613 (in Eng)CrossRefPubMed
19.
Robertson JF, Llombart-Cussac A, Rolski J et al (2009) Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. (Translated from Eng). J Clin Oncol 27(27):4530–4535 (in Eng)CrossRefPubMed
20.
Mehta RS, Barlow WE, Albain KS et al (2012) Combination anastrozole and fulvestrant in metastatic breast cancer. (Translated from Eng). N Engl J Med 367(5):435–444 (in Eng)CrossRefPubMedCentralPubMed
21.
Bergh J, Jonsson PE, Lidbrink EK et al (2012) FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. (Translated from Eng). J Clin Oncol 30(16):1919–1925 (in Eng)CrossRefPubMed
22.
Buzdar AU, Jonat W, Howell A et al (1998) Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. (Translated from Eng). Cancer 83(6):1142–1152 (in Eng)CrossRefPubMed
23.
Dombernowsky P, Smith I, Falkson G et al (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. (Translated from Eng). J Clin Oncol 16(2):453–461 (in Eng)PubMed
24.
Buzdar A, Douma J, Davidson N et al (2001) Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. (Translated from Eng). J Clin Oncol 19(14):3357–3366 (in Eng)PubMed
25.
Kaufmann M, Bajetta E, Dirix LY et al (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. (Translated from Eng). J Clin Oncol 18(7):1399–1411 (in Eng)PubMed
26.
Rose C, Vtoraya O, Pluzanska A et al (2003) An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. (Translated from Eng). Eur J Cancer 39(16):2318–2327 (in Eng)CrossRefPubMed
27.
Robertson JF, Osborne CK, Howell A et al (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. (Translated from Eng). Cancer 98(2):229–238 (in Eng)CrossRefPubMed
28.
Lonning PE, Bajetta E, Murray R et al (2000) Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. (Translated from Eng). J Clin Oncol 18(11):2234–2244 (in Eng)PubMed
29.
Iaffaioli RV, Formato R, Tortoriello A et al (2005) Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. (Translated from Eng). Br J Cancer 92(9):1621–1625 (in Eng)CrossRefPubMedCentralPubMed
30.
Steele N, Zekri J, Coleman R et al (2006) Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure. (Translated from Eng). Breast 15(3):430–436 (in Eng)CrossRefPubMed
31.
Thurlimann B, Robertson JF, Nabholtz JM et al (2003) Efficacy of tamoxifen following anastrozole (‘Arimidex’) compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. (Translated from Eng). Eur J Cancer 39(16):2310–2317 (in Eng)CrossRefPubMed
32.
Chia S, Gradishar W, Mauriac L et al (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. (Translated from Eng). J Clin Oncol 26(10):1664–1670 (in Eng)CrossRefPubMed
33.
Di Leo A, Jerusalem G, Petruzelka L et al (2010) Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. (Translated from Eng). J Clin Oncol 28(30):4594–4600 (in Eng)CrossRefPubMed
34.
Yamamoto Y, Ishikawa T, Hozumi Y et al (2013) Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer. (Translated from Eng). BMC Cancer 13:239 (in Eng)CrossRefPubMedCentralPubMed
35.
Yardley DA, Noguchi S, Pritchard KI et al (2013) Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. (Translated from Eng). Adv Ther 30(10):870–884 (in Eng)CrossRefPubMedCentralPubMed
36.
Johnston SR, Kilburn LS, Ellis P et al (2013) Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. (Translated from Eng). Lancet Oncol 14(10):989–998 (in Eng)CrossRefPubMed
37.
Manni A, Arafah BM, Pearson OH (1981) Androgen-induced remissions after antiestrogen and hypophysectomy in stage IV breast cancer. (Translated from Eng). Cancer 48(11):2507–2509 (in Eng)CrossRefPubMed
38.
Byrne MJ, Gebski V, Forbes J et al (1997) Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group. (Translated from Eng). J Clin Oncol 15(9):3141–3148 (in Eng)PubMed
39.
Paterson AH, Hanson J, Pritchard KI et al (1990) Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer. (Translated from Eng). Semin Oncol 17((6 Suppl 9)):52–62 (in Eng)PubMed
40.
Haddow A, Watkinson JM, Paterson E et al (1944) Influence of synthetic oestrogens on advanced malignant disease. (Translated from Eng). Br Med J 2(4368):393–398 (in Eng)CrossRefPubMedCentralPubMed
41.
Peethambaram PP, Ingle JN, Suman VJ et al (1999) Randomized trial of diethylstilbestrol vs tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. (Translated from Eng). Breast Cancer Res Treat 54(2):117–122 (in Eng)CrossRefPubMed
42.
Lonning PE, Taylor PD, Anker G et al (2001) High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. (Translated from Eng). Breast Cancer Res Treat 67(2):111–116 (in Eng)CrossRefPubMed
43.
Agrawal A, Robertson JF, Cheung KL (2006) Efficacy and tolerability of high dose “ethinylestradiol” in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents. (Translated from Eng). World J Surg Oncol 4:44 (in Eng)CrossRefPubMedCentralPubMed
44.
Mahtani RL, Stein A, Vogel CL (2009) High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review. (Translated from Eng). Clin Ther 31(Pt 2):2371–2378 (in Eng)CrossRefPubMed
45.
Ellis MJ, Gao F, Dehdashti F et al (2009) Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. (Translated from Eng). JAMA 302(7):774–780 (in Eng)CrossRefPubMedCentralPubMed
46.
Iwase H, Yamamoto Y, Yamamoto-Ibusuki M et al (2013) Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study. (Translated from Eng). Br J Cancer 109(6):1537–1542 (in Eng)CrossRefPubMedCentralPubMed
47.
Li S, Shen D, Shao J et al (2013) Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. (Translated from Eng). Cell Rep 4(6):1116–1130 (in Eng)CrossRefPubMed
48.
Jordan VC, Lewis-Wambi JS, Patel RR et al (2009) New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis. (Translated from Eng). Breast 18(Suppl 3):S10–17 (in Eng)CrossRefPubMedCentralPubMed
Metadata
Title
Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer
Authors
Hirotaka Iwase
Yutaka Yamamoto
Publication date
01-04-2015
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 2/2015
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-015-0793-8

Other articles of this Issue 2/2015

International Journal of Clinical Oncology 2/2015 Go to the issue

Original Article

Disease control and clinicopathological prognostic factors of total pharyngolaryngectomy for hypopharyngeal cancer: a single-center study

Original Article

[18F]fluoro-2-deoxyglucose-positron emission tomography for the assessment of histopathological response after preoperative chemoradiotherapy in advanced oral squamous cell carcinoma

Original Article

Opioid needs of terminally ill patients with gynecologic malignancies

Special Article

Japan Society of Gynecologic Oncology guidelines 2011 for the treatment of uterine cervical cancer

Original Article

Aggressive estrogen-receptor-positive breast cancer arising in patients with elevated body mass index

Original Article

Hyponatremia as a powerful prognostic predictor for Japanese patients with clear cell renal cell carcinoma treated with a tyrosine kinase inhibitor
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits